Xillix reduces loss on 31% revenue gain
This article was originally published in Clinica
In the 12 months ended August 31st, 1995, Xillix (Canada) reported a 31% increase in revenues to Can$5.6 million ($4.2 million) compared with fiscal 1994. The net loss for the period was reduced from Can$5.28 million to Can$4.35 million. The Richmond, British Columbia company is changing its fiscal year to a calendar year and will produce a report for the 16 months to December 31st, 1995.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.